Giving monoclonal antibody treatment to COVID-19 patients through injections is faster and about as effective as administering the therapy through IV, officials from UPMC said on Thursday.
The treatment, which has been used to alleviate severe COVID-19 symptoms in infected people, has typically been given through IV treatments, but giving it out via four injections takes less time and can be administered by more healthcare staff, according to a new study.
It is the first and largest clinical trial comparing these different methods of monoclonal antibody treatment, said Erin McCreary, an infectious diseases pharmacist at UPMC and a clinical assistant professor at the University of Pittsburgh’s School of Medicine.
The trial followed 2,000 patients over 28 days, and it found participants who received injections of Regeneron’s monoclonal antibodies had a 3.4% likelihood of being hospitalized or dying in those four weeks, compared to 7.8% in patients who were not treated. The findings were shared in a preprint journal, but have not yet been peer reviewed.
“We can more than double the number of patients that we treat this way, helping make sure that we are treating as many patients as possible and saving as many lives as possible,” Ms. McCreary said at the virtual news conference. She said people who are sick with COVID-19 should ask their doctors about monoclonal antibody treatments.
The Food and Drug Administration has given emergency authorization to the injection if IV infusion “is not feasible and would lead to delay in treatment.” Pharmaceutical companies have also been developing other treatments, such as an at-home COVID-19 pill from Merck, which an FDA panel narrowly approved this week.
Read More
The development of more treatments could help the fight against COVID-19 as cold-weather cases surge and doctors voice concern over the recently discovered omicron variant of the virus. Whether or not this treatment will work against the new variant of concern is still unknown, said Dr. Graham Snyder, UPMC’s medical director of infection prevention and hospital epidemiology.
“We can use the strength of our robust healthcare databases to know who is most vulnerable to infection and complications, and how well treatments work,” Dr. Snyder said.
Officials will also continue to track breakthrough infections among vaccinated healthcare workers to determine how effective the shots are against omicron, a variant that “we still have much to learn about,” he said.
While the majority of UPMC’s employees have received the shots, a court order this week halted the Biden administration’s mandate for most healthcare workers to get vaccinated against COVID-19, a rule that could affect 76,000 facilities and 17 million employees nationally.
UPMC’s chief medical officer, Dr. Donald Yealy, said at the news conference that the network would closely watch what the courts decided and follow whatever ruling comes down, and would continue educating and encouraging employees toward vaccinating.
He stopped short, however, of saying that UPMC would makes its own requirement for employees to get vaccinated if the federal mandate were blocked permanently, even as doctors have emphasized the vaccine as one of the most effective way to keep people safe from the virus.
“We will comply with whatever mandate exists, and we will continue our activities that encourage and try to increase vaccination,” he said. “I can’t say any more than that.”
One of the biggest challenges facing the healthcare network is hospital capacity, Dr. Yealy said, as more COVID-19 patients are admitted and the industry experiences a nationwide staffing shortage. “We are aggressively changing how we recruit, retain and advance our employees.”
Most facilities in the healthcare network are operating “near the high end” of their capacities, but UPMC has been adapting to those challenges for a long time, he said.
“It’s a challenge, it’s hard work right now,” he said. “We’re up to that challenge, and I’m comfortable that we’ll continue on that pathway.”
Mick Stinelli: mstinelli@post-gazette.com; 412-263-1869; and on Twitter: @MickStinelli





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.